Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (25839) 25839
Book Chapter (412) 412
Newsletter (140) 140
Newspaper Article (113) 113
Conference Proceeding (38) 38
Magazine Article (37) 37
Dissertation (34) 34
Book / eBook (15) 15
Publication (12) 12
Transcript (6) 6
Government Document (2) 2
Trade Publication Article (2) 2
Book Review (1) 1
Paper (1) 1
Reference (1) 1
Report (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (19752) 19752
life sciences & biomedicine (17629) 17629
humans (16884) 16884
male (7038) 7038
female (6736) 6736
animals (6508) 6508
risk factors (5551) 5551
biological and medical sciences (5211) 5211
cardiovascular system & cardiology (4607) 4607
hematology (4322) 4322
medical sciences (3883) 3883
middle aged (3876) 3876
aged (3487) 3487
anticoagulants (3415) 3415
peripheral vascular disease (3248) 3248
adult (3203) 3203
time factors (2845) 2845
factor xa inhibitors (2704) 2704
anticoagulants - therapeutic use (2401) 2401
analysis (2390) 2390
biochemistry & molecular biology (2343) 2343
research (2288) 2288
treatment outcome (1947) 1947
fundamental and applied biological sciences. psychology (1941) 1941
abridged index medicus (1928) 1928
mice (1872) 1872
thrombosis (1823) 1823
cardiac & cardiovascular systems (1801) 1801
pharmacology & pharmacy (1764) 1764
proteins (1702) 1702
thrombin (1675) 1675
anticoagulants - administration & dosage (1655) 1655
factor xa (1655) 1655
anticoagulants - adverse effects (1591) 1591
health aspects (1584) 1584
care and treatment (1502) 1502
pharmacology. drug treatments (1485) 1485
blood coagulation - drug effects (1474) 1474
factor xa - metabolism (1462) 1462
thromboembolism (1448) 1448
atrial fibrillation (1426) 1426
aged, 80 and over (1407) 1407
administration, oral (1359) 1359
research article (1354) 1354
rivaroxaban (1346) 1346
cell biology (1313) 1313
medicine & public health (1304) 1304
anticoagulants - pharmacology (1269) 1269
science & technology - other topics (1269) 1269
stroke (1259) 1259
blood coagulation (1251) 1251
physical sciences (1248) 1248
kinetics (1246) 1246
hemorrhage - chemically induced (1216) 1216
heparin (1197) 1197
gene expression (1192) 1192
molecular and cellular biology (1187) 1187
multidisciplinary sciences (1180) 1180
dose-response relationship, drug (1179) 1179
rats (1176) 1176
medicine (1170) 1170
oncology (1149) 1149
protein binding (1118) 1118
coagulation (1099) 1099
molecular sequence data (1088) 1088
general & internal medicine (1078) 1078
adolescent (1074) 1074
studies (1063) 1063
surgery (1063) 1063
blood. blood coagulation. reticuloendothelial system (1057) 1057
binding sites (1042) 1042
patients (1035) 1035
blood coagulation. blood cells (1032) 1032
amino acid sequence (1007) 1007
thrombin - metabolism (977) 977
atrial fibrillation - drug therapy (972) 972
tissue factor (961) 961
cancer (955) 955
retrospective studies (937) 937
neurosciences & neurology (936) 936
physiological aspects (933) 933
drug therapy (929) 929
factor xa inhibitors - therapeutic use (920) 920
risk assessment (915) 915
inflammation (911) 911
chemistry (896) 896
signal transduction (892) 892
technology (887) 887
stroke - prevention & control (885) 885
thromboplastin - metabolism (865) 865
warfarin (861) 861
cells, cultured (857) 857
hematologic and hematopoietic diseases (852) 852
mortality (851) 851
medicine, general & internal (840) 840
genetic aspects (835) 835
science (831) 831
prevention (829) 829
prospective studies (822) 822
coagulation factors (819) 819
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (3) 3
Robarts - Stacks (3) 3
UofT at Scarborough - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
OISE - Stacks (1) 1
Online Resources - Online (1) 1
Trinity College (John W Graham) - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (26102) 26102
German (222) 222
Japanese (162) 162
French (144) 144
Portuguese (89) 89
Russian (84) 84
Spanish (81) 81
Italian (33) 33
Chinese (29) 29
Polish (28) 28
Czech (21) 21
Norwegian (14) 14
Hungarian (13) 13
Swedish (9) 9
Turkish (7) 7
Korean (6) 6
Bulgarian (3) 3
Danish (3) 3
Slovenian (3) 3
Dutch (2) 2
Romanian (2) 2
Slovak (2) 2
Afrikaans (1) 1
Bosnian (1) 1
Lithuanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor
by Becker, Richard C and Yang, Hongqiu and Barrett, Yuchen and Mohan, Puneet and Wang, Jessie and Wallentin, Lars and Alexander, John H
Journal of thrombosis and thrombolysis, ISSN 0929-5305, 8/2011, Volume 32, Issue 2, pp. 183 - 187
Medicine & Public Health | Hematology | Cardiology | Acute coronary syndrome | Ant-Xa activity | Apixaban | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Pyridones - pharmacokinetics | Humans | Middle Aged | Male | Factor Xa - metabolism | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Pyridones - administration & dosage | Pyrazoles - administration & dosage | Blood Coagulation Tests - methods | Female | Aged | Anticoagulants - pharmacokinetics | Pyrazoles - pharmacokinetics | Medical colleges | Safety regulations | Analysis | Cardiac patients | Liquid chromatography | Coronary heart disease | Mass spectrometry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
by M. M. Samama and J.-L. Martinoli and L. LeFlem and C. Guinet and G. Plu-Bureau and F. Depasse and E. Perzborn
Thrombosis and haemostasis, ISSN 0340-6245, 04/2010, Volume 103, Issue 4, pp. 815 - 825
fondaparinux | rivaroxaban | Clotting assays | venous thromboembolism | pharmacodynamics | Factor Xa inhibitor | New Technologies, Diagnostic Tools and Drugs | Rivaroxaban | Pharmacodynamics | Venous thromboembolism | Fondaparinux | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Cardiology. Vascular system | Hematologic and hematopoietic diseases | Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Blood and lymphatic vessels | Platelet diseases and coagulopathies | Predictive Value of Tests | Factor Xa Inhibitors | Humans | Prothrombin Time | Fibrinolytic Agents - blood | Thiophenes - administration & dosage | Blood Coagulation Tests - standards | Drug Monitoring - methods | Morpholines - blood | Thiophenes - blood | Dose-Response Relationship, Drug | Time Factors | Reproducibility of Results | Thrombelastography | Administration, Oral | Morpholines - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Calibration | Polysaccharides - pharmacology | Drug Monitoring - standards | Fibrinolytic Agents - pharmacology | Blood Coagulation - drug effects | Partial Thromboplastin Time | Fibrinolytic Agents - administration & dosage | Thrombin - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
by Ruff, Christian T., MD and Giugliano, Robert P., MD, SM and Antman, Elliott M., MD and Crugnale, Sharon E., MS and Bocanegra, Tomas, MD and Mercuri, Michele, MD, PhD and Hanyok, James, PharmD and Patel, Indravadan, MD and Shi, Minggao, PhD and Salazar, Dan, PhD and McCabe, Carolyn H., BS and Braunwald, Eugene, MD
The American heart journal, ISSN 0002-8703, 2010, Volume 160, Issue 4, pp. 635 - 641.e2
Cardiovascular | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiology. Vascular system | Heart | Cardiac dysrhythmias | Biological and medical sciences | Myocarditis. Cardiomyopathies | Medical sciences | Coronary heart disease | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Follow-Up Studies | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Thiazoles - therapeutic use | Atrial Fibrillation - physiopathology | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Thrombolytic Therapy - methods | Electrocardiography | Female | Myocardial Infarction - physiopathology | Retrospective Studies | Pyridines - therapeutic use | Stroke - prevention & control | Pyridines - administration & dosage | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Myocardial Infarction - complications | Stroke - etiology | Myocardial Infarction - drug therapy | Aged | Warfarin | Care and treatment | Comparative analysis | Atrial fibrillation | Heart attack | Women | Anticoagulants | Cardiac arrhythmia | Hepatitis | Nonsteroidal anti-inflammatory drugs | Drug therapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor
by A. G. G. Turpie and R. Kreutz and J. Llau and B. Norrving and S. Haas
Thrombosis and haemostasis, ISSN 0340-6245, 11/2012, Volume 108, Issue 5, pp. 876 - 886
Recommendations | rivaroxaban | practical management | anticoagulant | Consensus Paper | Rivaroxaban | Anticoagulant | Practical management | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Hematologic and hematopoietic diseases | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Platelet diseases and coagulopathies | Thiophenes - therapeutic use | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Male | Thiophenes - administration & dosage | Dabigatran | Warfarin - administration & dosage | Venous Thromboembolism - prevention & control | Benzimidazoles - administration & dosage | Arthroplasty, Replacement, Knee | Female | Venous Thrombosis - prevention & control | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Morpholines - therapeutic use | Blood Loss, Surgical - prevention & control | Stroke - prevention & control | Venous Thrombosis - drug therapy | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Clinical Trials as Topic | Anticoagulants - adverse effects | Pregnancy | Practice Guidelines as Topic | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | recommendations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
by Siegal, Deborah M and Curnutte, John T and Connolly, Stuart J and Lu, Genmin and Conley, Pamela B and Wiens, Brian L and Mathur, Vandana S and Castillo, Janice and Bronson, Michele D and Leeds, Janet M and Mar, Florie A and Gold, Alex and Crowther, Mark A
The New England journal of medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2413 - 2424
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Rivaroxaban - adverse effects | Female | Factor Xa - therapeutic use | Prothrombin - metabolism | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Antidotes - pharmacology | Peptide Fragments - metabolism | Double-Blind Method | Administration, Oral | Recombinant Proteins - pharmacology | Factor Xa - metabolism | Protein Precursors - metabolism | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Blood Coagulation - drug effects | Factor Xa - pharmacology | Factor Xa Inhibitors - adverse effects | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Antidotes - therapeutic use | Treatment outcome | Usage | Analysis | Clinical trials | Anticoagulants (Medicine) | Dosage and administration | Hemorrhage | Risk factors | Prevention | Anticoagulants | Side effects | Inhibitor drugs | Prothrombin | Thrombin | Thrombosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Assessment of apixaban plasma levels by laboratory tests: Suitability of three anti-Xa assays a multicentre french GEHT study
by Gouin-Thibault, Isabelle and Flaujac, Claire and Delavenne, Xavier and Quenet, Sara and Horellou, Marie-Hélenè and Laporte, Silvy and Siguret, Virginie and Lecompte, Thomas
Thrombosis and haemostasis, ISSN 0340-6245, 10/2013, Volume 111, Issue 2, pp. 240 - 248
Anti-xa | Blood coagulation tests | Anticoagulant agents | Multicenter study | Apixaban | Fundamental and applied biological sciences. Psychology | Hematologic and hematopoietic diseases | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Platelet diseases and coagulopathies | Predictive Value of Tests | Reproducibility of Results | Factor V - metabolism | Factor Xa Inhibitors | Laboratory Proficiency Testing | Humans | Prothrombin Time | Blood Coagulation Tests - standards | Drug Monitoring - methods | Pyridones - blood | Anticoagulants - blood | Drug Monitoring - standards | Reference Standards | Blood Coagulation - drug effects | Partial Thromboplastin Time | Pyrazoles - blood | France | Prothrombin - metabolism | Observer Variation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
by Y. C. Barrett and Z. Wang and C. Frost and A. Shenker
Thrombosis and haemostasis, ISSN 0340-6245, 12/2010, Volume 104, Issue 6, pp. 1263 - 1271
prothrombin time | anti-Xa activity | Factor Xa inhibitor | international normalised ratio | Apixaban | New Technologies, Diagnostic Tools and Drugs | Anti-Xa activity | International normalised ratio | Prothrombin time | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Hematologic and hematopoietic diseases | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Platelet diseases and coagulopathies | Predictive Value of Tests | Pyrazoles - therapeutic use | Reproducibility of Results | Factor Xa Inhibitors | Humans | Prothrombin Time | Anticoagulants - therapeutic use | Drug Monitoring - methods | Morpholines - blood | Thiophenes - blood | Pyridones - blood | Venous Thromboembolism - drug therapy | Anticoagulants - blood | Venous Thromboembolism - blood | Dose-Response Relationship, Drug | International Normalized Ratio | Rivaroxaban | Blood Coagulation - drug effects | Pyrazoles - blood | Blood Coagulation Tests | Isoxazoles - blood | Pyridones - therapeutic use | Clinical Trials, Phase II as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor
by PERZBORN, E and STRASSBURGER, J and WILMEN, A and POHLMANN, J and ROEHRIG, S and SCHLEMMER, K‐H and STRAUB, A
Journal of thrombosis and haemostasis, ISSN 1538-7933, 03/2005, Volume 3, Issue 3, pp. 514 - 521
antithrombotic activity | oral anticoagulant | Factor Xa inhibitor | Oral anticoagulant | Antithrombotic activity | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Rabbits | Factor Xa Inhibitors | Species Specificity | Venous Thrombosis - drug therapy | Humans | Morpholines - pharmacology | Rats | Dose-Response Relationship, Drug | Serine Proteinase Inhibitors - therapeutic use | Fibrinolytic Agents - pharmacology | Rivaroxaban | Animals | Thiophenes | Fibrinolytic Agents - therapeutic use | Blood Coagulation Tests | Inhibitory Concentration 50 | Venous Thrombosis - prevention & control | Thromboplastin - metabolism | Serine Proteinase Inhibitors - pharmacology | Disease Models, Animal | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Oral Direct Factor Xa Inhibitors
by Yeh, Calvin H and Fredenburgh, James C and Weitz, Jeffrey I
Circulation research, ISSN 0009-7330, 09/2012, Volume 111, Issue 8, pp. 1069 - 1078
heparin | thrombosis | rivaroxaban | factor Xa inhibitors | apixaban | edoxaban | warfarin | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Biological and medical sciences | Vertebrates: cardiovascular system | Animals | Factor Xa Inhibitors | Anticoagulants - pharmacology | Humans | Drug Design | Pyridines - pharmacology | Thiazoles - pharmacology | Thrombosis - drug therapy | Thrombosis - blood | Pyridones - pharmacology | Pyrazoles - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Antidote for Factor Xa Anticoagulants
by Connors, Jean M
The New England journal of medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2471 - 2472
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Hemorrhage - drug therapy | Factor Xa Inhibitors - adverse effects | Humans | Female | Male | Factor Xa - therapeutic use | Anticoagulants (Medicine) | Dosage and administration | Antidotes | Research | Studies | Plasma | Anticoagulants | Side effects | Inhibitor drugs | Fibrillation | Thrombin | Antagonists | Drug development | Hemorrhage | Drug dosages | Vitamin K | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
by Connolly, Stuart J and Milling, Truman J and Eikelboom, John W and Gibson, C. Michael and Curnutte, John T and Gold, Alex and Bronson, Michele D and Lu, Genmin and Conley, Pamela B and Verhamme, Peter and Schmidt, Jeannot and Middeldorp, Saskia and Cohen, Alexander T and Beyer-Westendorf, Jan and Albaladejo, Pierre and Lopez-Sendon, Jose and Goodman, Shelly and Leeds, Janet and Wiens, Brian L and Siegal, Deborah M and Zotova, Elena and Meeks, Brandi and Nakamya, Juliet and Lim, W. Ting and Crowther, Mark and ANNEXA-4 Investigators
The New England journal of medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 12, pp. 1131 - 1141
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Prospective Studies | Humans | Male | Intracranial Hemorrhages - drug therapy | Recombinant Proteins - adverse effects | Enoxaparin - adverse effects | Cardiovascular Diseases - complications | Intracranial Hemorrhages - diagnosis | Rivaroxaban - adverse effects | Aged, 80 and over | Female | Factor Xa - therapeutic use | Gastrointestinal Hemorrhage - drug therapy | Factor Xa - adverse effects | Pyrazoles - adverse effects | Acute Disease | Gastrointestinal Hemorrhage - chemically induced | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Thrombosis - etiology | Factor Xa Inhibitors - adverse effects | Intracranial Hemorrhages - chemically induced | Factor Xa Inhibitors - metabolism | Aged | Hemorrhage - chemically induced | Infusions, Intravenous | Pyridones - adverse effects | Care and treatment | Anticoagulants (Medicine) | Research | Management | Hemorrhage | Patients | Enzymes | Hemostasis | Coagulation | Cardiovascular diseases | Drug therapy | Bleeding | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights